Results 1 to 10 of about 6,002 (227)

Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial [PDF]

Journal for ImmunoTherapy of Cancer
Background The recent phase II randomized stereotactic ablative radiotherapy with and without immunotherapy (I-SABR) trial has shown improved event-free survival (EFS) when adding immunotherapy to stereotactic ablative radiotherapy (SABR) for early-stage
Vivek Verma, Jianjun Zhang, John V Heymach, Joe Y Chang, Steven H Lin, Saumil Gandhi, J Jack Lee, Caroline Chung, Jia Wu, Xinyan Xu, Muhammad Aminu, Natalie I Vokes, Eman Showkatian, Qasem Al-Tashi, Morteza Salehjahromi, Sheeba J Sujit, Yuliya Kitsel, Zhongxing Liao, Maliazurina B Saad, Muhamed Qayati Mohamed, David Qian, David Jaffray   +21 more
doaj   +2 more sources

Daily adaptive MR-guided stereotactic ablative re-irradiation (re-SABR) in oligometastatic liver disease: A single-institution retrospective analysis [PDF]

Clinical and Translational Radiation Oncology
Objective: Stereotactic ablative body radiotherapy (SABR) is an established treatment option in oligometastatic liver disease. Limited data exist on liver SABR re-irradiation (re-SABR).
Elena Moreno-Olmedo, Dan Murray, Ben George, Paul Bassett, Andy Gaya, Veni Ezhil, Somnath Mukherjee, Rebecca Muirhead, Ramanivas Sundareyan, Peter Dickinson, James Good, Kasia Owczarczyk   +11 more
doaj   +2 more sources

DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR [PDF]

Clinical and Translational Radiation Oncology, 2020
Purpose: To determine the effect of dose fractionation and time delay post-neoadjuvant stereotactic ablative radiotherapy (SABR) on dynamic contrast-enhanced (DCE)-MRI parameters in early stage breast cancer patients.
Matthew Mouawad, Heather Biernaski, Muriel Brackstone, Michael Lock, Brian Yaremko, Olga Shmuilovich, Anat Kornecki, Ilanit Ben Nachum, Giulio Muscedere, Kalan Lynn, Frank S. Prato, R. Terry Thompson, Stewart Gaede, Neil Gelman   +13 more
doaj   +2 more sources

Optimizing stereotactic ablative body radiotherapy for ultra-central lung lesions: a comparative dosimetric analysis [PDF]

Radiation Oncology
Background Stereotactic ablative body radiotherapy (SABR) for ultra-central (UC) lung tumors is still challenging due to potentially severe complications caused by overdoses to critical mediastinal structures.
Dan Tao, Lisi Sun, Lulu Wang, Lina Yang, Wei Zhou, Xiumei Tian, Xianfeng Liu   +6 more
doaj   +2 more sources

Stereotactic ablative radiotherapy for patients with hepatocellular carcinoma: analysis of post-treatment radiology and explant histology [PDF]

BJC Reports
Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment modality for hepatocellular carcinoma (HCC). Evaluation of tumour responses following SABR are currently based on conventional radiological criteria used for locoregional
Nekisa Zakeri, Ramanivas Sundareyan, Owen Cain, James Good, Tahir Shah, Shishir Shetty   +5 more
doaj   +2 more sources

HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR) [PDF]

Cancers, 2022
, , Heon Joo Park
exaly   +2 more sources

Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell Carcinoma [PDF]

Advances in Radiation Oncology
Purpose: The optimal management strategies for glandular metastases in patients with metastatic renal cell carcinoma (mRCC) are currently unknown. While local therapy may be effective, there is a paucity of data on Stereotactic Ablative Body Radiation ...
Mihailo Miljanic, MD, Tidie Song, BS, Alana Christie, MS, Allen Yen, MD, Young Suk Kwon, MD, MPH, Aurelie Garant, MD, Todd A. Aguilera, MD, PhD, Zabihullah Wardak, MD, Hans Hammers, MD, Kevin Courtney, MD, PhD, Suzanne Cole, MD, James Brugarolas, MD, PhD, Robert Timmerman, MD, Raquibul Hannan, MD, PhD   +13 more
doaj   +2 more sources

PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer. [PDF]

Clin Transl Radiat Oncol
Zang AL, Maier T, Freitag-Wolf S, Fabian A, Rodler S, Dunst J, Krug D, Lützen U, Wittenstein O.   +8 more
europepmc   +3 more sources

Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type [PDF]

Journal of Urologic Oncology, 2023
Renal cell carcinoma (RCC) has traditionally been considered one of the most radioresistant tumors based on in vitro and clinical studies that utilized a low biologically effective dose.
Chan Woo Wee, Jaeho Cho
doaj   +1 more source

Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care. [PDF]

Tech Innov Patient Support Radiat Oncol
Moreno-Olmedo E, Owczarczyk K, Chadwick E, Dickinson P, Duffton A, Jones B, Good JS, McDonald F, Murray LJ, Rackley T, Robinson M, Sinclair J, Strawson-Smith T, Tree A, Tsang YM, Zarkar A, Dean C, Díez P, Williams M, Andratschke N, Muirhead R.   +20 more
europepmc   +2 more sources